key: cord-0955914-mdc50zzl authors: Liu, Dongling; Zeng, Xiang; Ding, Zufeng; Lv, Fenghua; Mehta, Jawahar L.; Wang, Xianwei title: Adverse Cardiovascular Effects of Anti-COVID-19 Drugs date: 2021-08-25 journal: Front Pharmacol DOI: 10.3389/fphar.2021.699949 sha: dddfee703633eb5b9b9934fd170f5c39147de58c doc_id: 955914 cord_uid: mdc50zzl Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 infection is the cause of the ongoing global pandemic. Mortality from COVID-19 infection is particularly high in patients with cardiovascular diseases. In addition, COVID-19 patients with preexisting cardiovascular comorbidities have a higher risk of death. Main cardiovascular complications of COVID-19 are myocardial infarction, myocarditis, acute myocardial injury, arrhythmias, heart failure, stroke, and venous thromboembolism. Therapeutic interventions in terms of drugs for COVID-19 have many cardiac adverse effects. Here, we review the relative therapeutic efficacy and adverse effects of anti-COVID-19 drugs. Coronavirus disease 2019 (COVID-19) is a current global, emerging, and pandemic respiratory disease caused by an infection of SARS-CoV-2 . SARS-CoV-2 is a kind of RNA virus with a characteristic envelope and a linear single positive strand genome, which is different from severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) in infectivity and gene structure Rabaan et al., 2020; Shereen et al., 2020) . So far, there were more than 183 million documented global cases of COVID-19 and 4 million deaths according to reports of the World Health Organization (WHO) and Johns Hopkins University (Johns Hopkins University, 2021; WHO, 2021) . In other words, the global pandemic of COVID-19 infection is still serious, although vaccines from different countries and companies have been used worldwide (Dong et al., 2020; Kissler et al., 2020; Zhang et al., 2020a) . Therefore, it is necessary to discuss the adverse effects of different therapies. So far, the main anti-COVID-19 therapies are drug treatments. However, there are few effective drugs, and cardiovascular complications of drugs and SARS-CoV-2 mutation make it harder for potential drugs to effectively control the COVID-19 pandemic (Hamid et al., 2020) . COVID-19 is more than just a lung disease, and cardiovascular complications are common and serious in patients with COVID-19 Lala et al., 2020; Lang et al., 2020; Liu et al., 2020d; Madjid et al., 2020) . COVID-19 patients with cardiovascular and respiratory comorbidities contribute to the highest case fatality rate ( Figure 1 ) (CDC, 2020a; Clerkin et al., 2020; Giustino et al., 2020; Kunutsor and Laukkanen, 2020; Qiu et al., 2020) . Cardiovascular disease patients are more susceptible to SARS-CoV-2 and more likely to develop severe COVID-19 (Akhmerov and Marbán, 2020; Chung et al., 2020; Driggin et al., 2020; Han, 2020; Katz et al., 2020; Mahmud et al., 2020) . In particular, children with COVID-19 have also been reported to develop hyperinflammatory shock with characteristics similar to Kawasaki disease, including abnormalities of the coronary vessels and cardiac dysfunction (Akca et al., 2020; Alizargar, 2020; Toubiana et al., 2020) . Common cardiovascular complications of COVID-19 are arrhythmias, direct cardiac injury, fulminant myocarditis, acute myocardial infarction, heart failure, pulmonary embolism, and disseminated intravascular coagulation (Aid et al., 2020; Barison et al., 2020; Guzik et al., 2020; Long et al., 2020; Maleszewski et al., 2020; Matsushita et al., 2020) . Cytokine storm is associated with the severity and mortality of COVID-19 patients, which may be regulated by a key inflammation regulator known as the NLRP3 inflammasome Liu et al., 2020a; Ruscitti et al., 2020; . Excess activation of NLRP3 inflammasome increases the cardiovascular complication in COVID-19 patients (Bertocchi et al., 2020; Freeman and Swartz, 2020; Paniri and Akhavan-Niaki, 2020) . However, to date, little is known about the cardiovascular complications of anti-COVID-19 drug therapy. Current common anti-COVID-19 therapies include antiviral treatment, immunotherapy, convalescent plasma, traditional Chinese medicine, oxygen therapy, nutritional support, mechanical ventilation, and nursing care (CDC, 2020b; Inglis et al., 2020; Nih, 2021; Yetman and Vinetz, 2021) . It is important to understand in-depth the cardiovascular complications of anti-COVID-19 therapy to further define the benefit of drug treatment strategies. Here, we summarize the cardiovascular complications of anti-COVID-19 drugs and discuss the performance of various treatment options to shed light on drug therapies for COVID-19. . The mechanisms for the cardiovascular complications of COVID-19 are still not fully understood. However, the main pathways of cardiovascular complications of anti-COVID-19 drugs have been proposed are listed as follows ( Figure 2 ): 1) direct cardiotoxicity; 2) systemic inflammation; 3) mismatch of myocardial supply and demand; 4) plaque rupture and thrombosis of coronary; 5) disseminated intravascular coagulation due to sepsis; 6) imbalances of electrolyte; 7) endotheliitis and 8) hypercoagulability (Bansal, 2020; Kang et al., 2020; Nishiga et al., 2020; Nägele et al., 2020; Varga et al., 2020) . There is a common consensus that receptor-mediated endocytosis is the main way for the virus to enter cells. Up to now, a well-known molecular mechanism of COVID-19 is that SARS-CoV-2 can directly or indirectly invade humans by binding to angiotensin converting enzyme 2 [ACE2, an important component of the renin-angiotensin-aldosterone system (RAS)], which can lead to alterations in the ACE2 signaling pathway and subsequently induce lung and myocardial injury ( Figure 3 ) (Liu et al., 2020g; Brojakowska et al., 2020; Sharma, 2020; Wang et al., 2020b; Wang et al., 2020d; Zheng et al., 2020; Zhou et al., 2020) . The interaction of SARS-CoV-2 with RAS leads to electrolyte imbalance and results in hypokalemia (Lumpuy-Castillo et al., 2020) . As RAS inhibitors, angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and statins were used to decrease the risk of COVID-19 infection or severity by improving endothelial dysfunction (Liu et al., 2020f; De Spiegeleer et al., 2020; Lee et al., 2020; Nägele et al., 2020) . Although some studies challenged ACEIs/ARBs/statin therapy for COVID-19, ACEIs/ARBs/statin treatment should continue in patients with COVID-19 based on available reported evidence (Liu et al., 2020d; Fosbol et al., 2020; Hasan et al., 2020; Mehta et al., 2020; Zhang et al., 2020d; Zhang et al., 2020e; Tetlow et al., 2021) . The most severe cases of COVID-19 are characterized by an acute systemic inflammatory response, cytokine storm, endotheliitis, and hypercoagulability. Systemic infection, coupled with hypoxia, can lead to imbalance/mismatch of the myocardial supply and demand ratio. Increased of systemic inflammation and shear stress due to elevated coronary blood flow causes plaque rupture and subsequent arrhythmias, acute myocardial infarction, and heart failure. It is well known that endothelial cells play a crucial role in the maintenance and regulation of vascular homeostasis and coagulation. Endodermatitis, characterized by endothelial dysfunction and hypercoagulability, is a common feature of major comorbidities that increase the risk of severe COVID-19 (Becker, 2020; Fan et al., 2020; Panigada et al., 2020) . Common treatment of COVID-19 patients with cardiovascular complications includes traditional care, coronary angiography and percutaneous coronary intervention if indicated, the use of anticoagulants and antiplatelet agents, and supportive care. Some patients with circulatory collapse may need extracorporeal circulatory support. Next, we briefly summarize the cardiovascular complications of anti-COVID-19 drug therapy ( Table 1) . Lopinavir is a human immunodeficiency virus (HIV) protease inhibitor, which was approved by the US Food and Drug Administration (FDA) in 2000 and allowed for listing in China in 2008 (Oldfield and Plosker, 2006) . Lopinavir inhibits the action of the enzyme 3-chymotrypsin-like protease and P-glycoprotein, which plays a crucial role in the distribution and elimination of lopinavir . Ritonavir is used in combination with lopinavir because it can increase the half-life of lopinavir by inhibiting the metabolizing enzyme cytochrome P450 3A (Abbvie, 2020) . The combination of lopinavir and ritonavir has been preferred for the treatment of COVID-19 Li and De Clercq, 2020; Pillaiyar et al., 2020) . However, it has recently been shown to be ineffective according to a randomized controlled trial . Interestingly, common adverse reactions of the combination of lopinavir and ritonavir include hypertension, prolonged P-R and prolonged QT interval, torsade de pointes, severe conduction disorders, and cardiac arrhythmias (Badiou et al., 2003; Abbvie, 2012; Gerard et al., 2020) . Additionally, the combination of lopinavir/ritonavir can induce drug-related cardiotoxicity by regulating cardiomyocyte pyroptosis, lysosome-mediated protein degradation, calcium signaling pathway, and the phosphatidylinositol 3-kinase (PI3K)/protein serine threonine kinase (Akt) signaling pathway (Reyskens et al., 2013) . Therefore, changes in electrocardiograms and alteration of blood lipids should be monitored and checked in patients with COVID-19 and dyslipidemia. The current mode of administration of lopinavir/ritonavir is oral, and the recommended dose is twice a day and two capsules each time with 200 mg/50 mg/capsule for adults. The course of treatment lasts less than 10 days. Remdesivir is an inhibitor of viral RNA-dependent RNA polymerase (RdRp) with broad-spectrum activity against several members of the virus family such as coronaviruses (e.g., SARS-CoV and MERS-CoV) and filoviruses (e.g., Ebola). RdRp is essential for the replication of SARS-CoV-2 (Spinner et al., 2020) . Remdesivir is currently the only drug approved by the FDA for the treatment of COVID-19. It is usually used in hospitalization of patients who require supplemental oxygen. Until now, remdesivir and dexamethasone have been recommended as first-line antiviral therapy for COVID-19 Horby et al., 2020; Spinner et al., 2020) . Remdesivir shows an excellent antiviral infection ability in vivo experiment (EC50 0.77 μM; CC50 > 100 μM; SI > 129.87) compared to favipiravir, ribavirin, penciclovir, nitazoxanide, nafamostat, and chloroquine (Wang et al., 2020c) . Although remdesivir has a numerically faster time to clinical improvement than placebo in patients, there was no statistically significant difference between the two groups. Notably, remdesivir is not recommended for mild patients due to a high incidence of adverse events . Another larger study confirms that remdesivir was superior to placebo in shortening recovery time and reducing the incidence of adverse events (Beigel et al., 2020) . Known adverse events of remdesivir are hypotension, bradycardia, QTc prolongation, and T-wave abnormality (Gubitosa et al., 2020; Gupta et al., 2020; Touafchia et al., 2021) . IFN-α, a low molecular glycoprotein, is characterized by antiviral, antiproliferative, antidifferentiation, and immunoregulatory functions. IFN-α is used for the control of COVID-19 in light of the urgency to confront the COVID-19 pandemic (Hariramnile et al., 2020; Sallard et al., 2020; Wang and Fish, 2020a) . Type I interferon inhibited SARS-CoV-2 in vitro experiments (Mantlo et al., 2020) . The main adverse reactions of IFN-α include ischemic cardiomyopathy, arrhythmias, and hypertension or hypotension (Sleijfer et al., 2005; Pichler, 2006; Kuo et al., 2018) . In addition, it causes endothelial dysfunction by promoting the expression of factors related to oxidative stress (Buie et al., 2017) . IFN-α can also cause acute myocardial injury by enhancing atherosclerotic plaques polarization of in M1 macrophages and inhibit angiogenesis by regulating signal transduction and activator of transcription 1 (STAT1) and STAT3 (Nelson et al., 2015; Hsu et al., 2017) . The mode of administration of IFN-α is aerosol inhalation, and the recommended dose is 5 million units or equivalent mixed with 2 ml of sterile water twice per day for adults. Although the drug is administered locally in the respiratory tract, one should be vigilant of its cardiotoxicity and pay close attention to electrocardiogram changes, the development of acute myocardial infarction, and heart failure, especially in elderly patients with preexisting cardiovascular diseases. Ribavirin is a purine nucleoside analogue with broad-spectrum antiviral activity, which can effectively inhibit the proliferation of a variety of respiratory viruses. Ribavirin overdoses can increase the risks of bradycardia (17%), anemia (27%), and hypomagnesemia (45%) (Muller et al., 2007) . It is administered in different ways in various diseases . This drug can also be used in both pediatric and adult populations co-infected with hepatitis B and HIV. At present, ribavirin combined with interferon and/or lopinavir/ritonavir is recommended for patients with COVID-19 (Elfiky, 2020a; Elfiky, 2020b; Hung et al., 2020; Li and De Clercq, 2020) . Wang et al. reported that ribavirin can inhibit virus growth (EC 50 109.50 μM, CC 50 > 400 μM, SI > 3.65) in Vero E6 cells (Wang et al., 2020c) . Common adverse reactions of ribavirin include dyspnea and chest pain, especially in patients with COPD and asthma (Lu et al., 2015) . Long-term (lasting 13 days) and highdose (600 mg twice per day) ribavirin increased the risk of developing cardiovascular disease events and raised the risk of death in patients with cardiovascular disease (Beigel et al., 2017) . Ribavirin can induce mitochondrial toxicity and energy metabolism disorders of cardiomyocytes by promoting mitochondrial calcium metabolism disorders (Lafeuillade et al., 2001) . Therefore, ribavirin may increase the risk of cardiac dysfunction in patients with preexisting cardiovascular diseases. The recommended administration of ribavirin for COVID-19 is intravenous infusion (500 mg, 2-3 times a day) with interferon-α or lopinavir/ritonavir, and the duration of therapy is not longer than 10 days. Chloroquine is used mainly in the treatment of malarial and rheumatic diseases (Savarino et al., 2003; Wang et al., 2020c; Wu et al., 2020) . It served to treat COVID-19 patients due to the characteristic of inhibiting endosomal acidification required for virus-host cell fusion. Chloroquine has been the drug of choice for large-scale use in the treatment of COVID-19 patients due to its wide availability, proven safety record, and relatively low cost (Cui et al., 2020; Ledford, 2020; Shah et al., 2020) . However, excessive use of chloroquine can cause cardiovascular dysfunction such as hypotension, hypokalemia, QRS and QT prolongation, atrioventricular block, arrhythmias, and even coma (Wong, 2020) . In addition, COVID-19 patients receiving a combination of hydroxychloroquine and azithromycin had a longer QT interval than those taking hydroxychloroquine alone in a cohort study (Mercuro et al., 2020) . Furthermore, recent studies demonstrated that chloroquine and hydroxychloroquine were not effective drugs for COVID-19 (Brown et al., 2020; Cavalcanti et al., 2020; Ferner and Aronson, 2020; Rosenberg et al., 2020) . The therapeutic dose of drugs is in a narrow concentration range that requires appropriate doses for different populations. Common derivatives of chloroquine (CQ) are chloroquine phosphate (PCQ) and hydroxychloroquine (HCQ). PCQ, as an approved immune modulator, can effectively block SARS-CoV-2/ 2019-nCoV infection (EC 50 1.13 μM; CC 50 > 100 μM, SI > 88.50) in Vero E6 cells (Beigel et al., 2020) . PCQ can control the electrophysiological activity of the heart by regulating the energy metabolism of cardiac myocytes, voltagegated ion channels, calcium channel, and electrochemistry transporters (Mubagwa, 2020) . However, CQ can induce serious cardiovascular reactions such as arrhythmias, shock, and Adams-Stokes syndrome (Pareek et al., 2018) . Recently, several reviews have noted out that CQ and HCQ induce significant prolongation of the QT interval and potentially increase the risk of serious arrhythmias and sudden death (Aggarwal et al., 2020; Jankelson et al., 2020; Zhang et al., 2020g) . The structures and mechanisms of HCQ and CQ are similar to those of PCQ. Wang et al. showed that HCQ can effectively block the replication of SARS-CoV-2 in vitro and improve the clinical symptoms of patients with COVID-19 (Wang et al., 2020c) . Previous studies have shown that HCQ can reduce cardiovascular risk, especially the incidence of cardiac dysfunction in patients with myocardial infarction Rempenault et al., 2018; Schrezenmeier and Dörner, 2020) . Although the FDA has authorized the use of HCQ and CQ for the treatment of COVID-19, one still needs to be aware of its adverse cardiovascular reactions such as atrioventricular block, cardiomyopathy, and heart failure. Compared with CQ, HCQ is less toxic and more potent in inhibiting SARS-CoV-2 infection in vitro (Liu et al., 2020b) . There is no association between HCQ administration and the risk of composite endpoint of intubation or death based on an observational study (Geleris et al., 2020) . There is no proven benefit for the use of HCQ in patients with COVID-19. In addition, it is worth noting that CQ has been revoked with the emergency use authorization (EUA) by the FDA (Rome and Avorn, 2020). Baricitinib is known as an inhibitor of Janus-associated kinase (JAK), specifically referring to JAK1 and JAK2, which is approved by the FDA and the EU for the treatment of rheumatoid arthritis with high efficacy and safety records (Markham, 2017) . It was identified as the numb-associated kinase inhibitor (NAK) with selectivity of the adapter protein-2 complex (AP2)-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK) that are mediators or regulators of viral endocytosis (Stebbing et al., 2020) . Inhibition of AAK1 by baricitinib can interrupt virus entry into cells and subsequently stop intracellular assembly and virus replication. In summary, baricitinib against COVID-19 relies mainly on inhibiting cytokine release and SARS-CoV-2 endocytosis (Magro, 2020; Richardson et al., 2020; Zhang et al., 2020f) . A recent study found that baricitinib improved clinical conditions in 12 patients with mild and moderate COVID-19 (Cantini et al., 2020a) . Another study demonstrated that baricitinib had a lower fatality rate and admission to the ICU, but a higher discharge rate compared with controls at week 1 and week 2 (Cantini et al., 2020b) . However, baricitinib was not recommended to treat patients with severe COVID-19 with susceptible constitution, at least be cautious (Favalli et al., 2020) . Up to now, baricitinib and remdesivir have been vapproved by the FDA through emergency use authorization (EUA) for hospitalized COVID-19 patients (Kalil et al., 2021) . Nonetheless, baricitinib is not an approved standalone drug by the FDA for COVID-19 treatment. The common adverse effect of baricitinib on COVID-19 is hyperglycemia, infections, and thromboembolic events. Arbidol is a non-nucleoside antiviral drug mainly for the treatment of influenza and other viral infections, which has inhibitory effects on both enveloped and nonenveloped viruses (Boriskin et al., 2008; Liu et al., 2009; Blaising et al., 2014) . As a highly selective hemagglutinin inhibitor, arbidol can effectively target the hemagglutinin fusion machinery and prevent CoVs from anchoring the cell surface and invading cells (Blaising et al., 2014) . Arbidol can block the trimerization of the SARS-CoV-2 spike glycoprotein and host cell adhesion, and effectively inhibit SARS-CoV-2 in vitro (Deng et al., 2020; Vankadari, 2020; Wang et al., 2020e) . A recent study suggested that arbidol was superior to lopinavir/ritonavir against COVID-19 (Zhu et al., 2020) . The combination of arbidol and lopinavir/ritonavir was better than lopinavir/ritonavir in anti-COVID-19 therapy (Deng et al., 2020) . In addition, arbidol alone could be used to treat COVID-19 patients with mild symptoms . However, a recent study showed that neither arbidol nor lopinavir/ritonavir could beneficially affect the outcomes of COVID-19 patients, and contributed to adverse effects such as diarrhea, poor appetite, and abnormal liver function . Common cardiovascular adverse effects of arbidol include nausea, diarrhea, dizziness, liver injury, vomiting, and bradycardia. The recommended dose of arbidol for COVID-19 patients is 200 mg PO each time and three times per day, and the course of therapy is not longer than 10 days. Other common candidate antiviral drugs for COVID-19 are fapiravir, penciclovir, sofosbuvir, and galidesivir (Pillaiyar et al., 2020; Richardson et al., 2020; Wang et al., 2020c) . Their main adverse effects include hypotension and arrhythmias. Fapiravir is a broad-spectrum anti-influenza drug, which exerts an antiviral effect mainly by inhibiting RNA synthetase (Gao et al., 2020; Wang et al., 2020c) . Sofosbuvir is an FDA-approved drug that is mainly used to treat patients with hepatitis C with various genotypes. Sofosbuvir is converted in a host cell to its active form, nucleoside triphosphate through phosphorylation, which terminates RNA replication in the nascent viral genome through competition with the nucleotides of invasive viruses (Sayad et al., 2020) . Elfiky reported that sofosbuvir, ribavirin, remdesivir, galidesivir and tenofovir can be bound to COVID-19 RNA polymerase and are potent drugs against COVID-19 infection (Elfiky, 2020b) . In vitro experiments indicate that remdesivir (EC 50 0.77 μM; CC 50 > 100 μM; SI > 129.87), fapiravir (EC 50 61.88 μM, CC 50 > 400 μM, SI > 6.46) and penciclovir (EC 50 95.96 μM, CC 50 > 400 μM, SI > 4.17) can effectively inhibit SARS-CoV-2 (Wang et al., 2020c) . However, these drugs have their own cardiovascular risk. For example, Mulangu et al. (2019) reported that an Ebola patient who received remdesivir had hypotension and subsequently died due to cardiac arrest. Caldeira et al. (2018) suggested an increased risk of serious bradycardia among patients treated with sofosbuvir and amiodarone based on an observational study. Taken together, cardiovascular complications and risks of antiviral drugs need to be taken into account when used in COVID-19 patients. Anti-inflammatory and immunotherapy drugs can alter the workings of the immune system, so it can find, attack, and eliminate invasive pathogens and finally get rid of them. Thus, it is an efficient therapeutic option against viral infections, including patients with COVID-19 characterized by the cytokine storm (Aminjafari and Ghasemi, 2020; Blanco-Melo et al., 2020; Vabret et al., 2020) . Dexamethasone, as a representative anti-inflammatory drug, is a broad-spectrum immunosuppressor approved by the FDA with high activity and a long duration of action. It will inhibit the release and subsequent detrimental effect of cytokines to further combat symptoms of hyperinflammation or cytokine storm in COVID-19 (Lim and Pranata, 2020; Sharun et al., 2020) . Recently, preliminary clinical trials of dexamethasone have been approved by the WHO based on the significant improvement in reducing mortality by 35% in ventilated patients and 20% in other patients receiving oxygen (Horby et al., 2020; Patel et al., 2020; WHO, 2020) . However, there is a lack of clinical benefit of dexamethasone in non-critical patients without respiratory support such as ventilation or oxygen (Johnson and Vinetz, 2020; Lester et al., 2020) . Dexamethasone can increase mortality in patients without critical illness who did not receive respiratory support (Matthay and Thompson, 2020) . It is notable that a low dose of dexamethasone could only reduce the mortality of patients with severe COVID-19, but had no effect on the mortality of patients with mild and moderate COVID-19 patients; while high doses of dexamethasone contributed to more harm than good (Ahmed and Hassan, 2020; Prescott and Rice, 2020; Sterne et al., 2020) . Additionally, the combination of dexamethasone and remdesivir may reduce mortality, which has been recommended to treat COVID-19 patients with mild-moderate conditions (Garibaldi et al., 2020; Vetter et al., 2020; Jo et al., 2021) . It is worth noting that dexamethasone treatment can lead to several adverse effects such as arrhythmias, headache, agitation, dizziness, and increased appetite. Tocilizumab, a humanized recombinant monoclonal antibody against interleukin-6 (IL-6), can inhibit the activity of the IL-6 receptor by binding to its membrane-bound and soluble forms, and thus block the "cytokine storm" caused by IL-6 (Xie et al., 2019) . Recently, tocilizumab was used to treat COVID-19 patients at risk of cytokine storm (Brown et al., 2020) . However, the adverse effects of tocilizumab should not be ignored, such as cardiomyopathy and liver injury (Muhovic et al., 2020) . Gabay et al. (2016) found that tocilizumab induced cardiomyocyte apoptosis and mitochondrial oxidative stress resulting in cardiotoxicity, manifested as hypertension, hypercholesterolemia and myocardial infarction, which remind clinicians to pay attention to the above-mentioned adverse effects of tocilizumab when combating COVID-19. The most common adverse reactions and events were infections that were characterized by an increase in serum cholesterol, ALT, AST, and injection site reactions (Khiali et al., 2020) . found that tocilizumab alleviated inflammatory activity in COVID-19 patients. demonstrated that abnormally elevated C-reactive protein and the number of lymphocytes decreased in 84 and 37% of patients, respectively. The average discharge time of patients treated with tocilizumab was 15.1 days, and this therapy effectively improved mortality in patients with severe and critically ill COVID-19 . It is worth of mentioning that an increasing trend of IL-6 occurs immediately when tocilizumab usage is reduced. Alattar et al. (2020) showed that tocilizumab caused adverse events such as anemia, QT interval prolongation, and ananine aminotransferase increase. Morena et al. (2020) demonstrated that COVID-19 patients treated with tocilizumab experienced adverse events included thrombocytopenia, increase of hepatic enzymes, and serious bacterial and fungal infections. Hermine et al. (2021) reported that tocilizumab induced cardiovascular adverse events manifested by hypertension, anemia, lymphopenia, and neutropenia, and bacterial sepsis. Fu et al. (2020) pointed out that tocilizumab treatment inhibited the inflammatory storm, resulting in an improved clinical outcome. Castagné et al. (2019) found that tocilizumab was associated with an elevated cholesterol level, which decreased inflammatory proteins and restored the antiatherogenic function of HDL cholesterol. It should be used with caution in patients with dyslipidemia and hypertension. The recommended dose of tocilizumab for COVID-19 patients is 400 mg dissolved in 100 ml of 0.9% sodium chloride; infused in >1 h 2 times at most; while looking for an allergic reaction. Anakinra is one of the anti-interleukin 1 antagonist which can inhibit actions of IL-1 receptor to suppress the pathogeny of proinflammatory cytokine storm in COVID-19 (Aouba et al., 2020; Dos Santos, 2020; Jamilloux et al., 2020; Salvi and Patankar, 2020; Wu et al., 2020) . Therefore, it has been used for the treatment of COVID-19 patients. Several studies indicated that anakinra is a safe and effective drug combating COVID-19 patients with cytokine storm signs (Bilia et al., 2020; Cauchois et al., 2020; Haigh et al., 2020; Huet et al., 2020; Navarro-Millán et al., 2020; Bozzi et al., 2021; Pasin et al., 2021) . Cavalli et al. (2020) found that high-dose anakinra was associated with clinical improvement in 72% of patients with COVID-19 and acute respiratory distress syndrome in a retrospective cohort study. Langer-Gould et al. (2020) demonstrated that early identification and treatment of COVID-19 cytokine storm with anakinra significantly improved outcomes after mechanical ventilation. Kooistra et al. (2020) showed that anakinra can reduce clinical symptoms of hyperinflammation in critically ill COVID-19 patients. The main adverse effects of anakinra were hypersensitivities, hyperinfammation, breathing problem, nausea, vomiting diarrhea, headache, and joint pain (Hossen et al., 2020; Kooistra et al., 2020; Manjaly Thomas et al., 2020) . Convalescent plasma refers to plasma collected from COVID-19 convalescent patients, which can contribute to a safe and effective therapy for COVID-19 patients. Previous studies in a variety of viral respiratory diseases, such as SARS and MERS, indicated that convalescent plasma can reduce mortality. Therefore, convalescent plasma may provide a potential therapy for COVID-19 patients Tiberghien et al., 2020) . Notably, the efficacy of convalescent plasma against COVID-19 remains to be proved (Casadevall and Pirofski, 2020; Roback and Guarner, 2020) . Several observed studies found that plasma convalescent therapy is effective and specific for COVID-19 (Duan et al., 2020; Shen et al., 2020; . However, there is one point of view that convalescent plasma is ineffective for COVID-19 (Pathak, 2020; Rogers et al., 2020) . In a word, the efficacy of convalescent plasma therapy for COVID-19 is controversial. Adequately powered and randomized controlled trials are needed to confirm the efficacy of convalescent plasma therapy for COVID-19 (Bloch, 2020; Liu et al., 2020e) . Recently, several randomized controlled trials demonstrated that the efficiency in different cases using plasma convalescent therapy is inconsistent (Agarwal et al., 2020; Li et al., 2020c; Klassen et al., 2020; Simonovich et al., 2021) . However, convalescent plasma was found to be relatively safe, in more than 20,000 patients with a low incidence of severe adverse events (<1%) (Joyner et al., 2020) . The general known cardiovascular risks of plasma transfusion generally include transfusion-associated circulatory overload, hypercoagulablility, and thrombosis (Sanfilippo et al., 2021) . Traditional Chinese Medicine (TCM) is usually defined by a mixture of herbal plants or their extracts which comprise hundreds of constituents with various differing physiochemical properties (Zhou, 2020) . TCM is a unique health resource in China, which is also a vast and large untapped resource in the world. For example, artemisinin, a safe and effective antimalarial drug, was originally extracted from Artemisia annua by TCM scientific workers (Tu, 2016) . In addition, in view of the remarkable therapeutic effects that TCM achieved during the SARS epidemic in 2003, TCM raises hopes for the prevention and control of COVID-19 . Several TCMs have been recommended by the China National Health Commission to treat COVID-19 patients because the advantages far outweigh the disadvantages, which are characterized mainly by promoting neutrophil-mediated inflammation and reducing macrophagemediated anti-inflammatory activity (Wang et al., 2020f; Tong et al., 2020; Zhang, 2020b) . Over 90% of COVID-19 patients in China have been treated with TCM, and some studies showed relief of symptom, reducing the time of onset of fever and reducing the severity of the disease Liu et al., 2020c; Ren et al., 2020) . Ren et al., 2020; Tong et al., 2020; Wang et al., 2020f) . Different of the above-mentioned TCMs are used to treat different diseases and different courses of the same disease ( Table 2 ). The key mechanism of TCM is inflammation regulation . In addition, Frontiers in Pharmacology | www.frontiersin.org August 2021 | Volume 12 | Article 699949 9 TCM controls cardiovascular risk factors such as hypertension and diabetes (Hao et al., 2017) . Although attention should be paid to the possible adverse effects of TCM, the benefits of TCM in the treatment of COVID-19 are also obvious (Gray and Belessis, 2020; An et al., 2021; Ren et al., 2021) . So far, the integration of TCM and Western medicine is effective for COVID based on previous pharmacological studies Ni et al., 2020; Xu and Zhang, 2020) . A combination of drugs can on one hand be beneficial and on the other hand harmful because of side effects. Lopinavir and ritonavir are metabolized by CYP3A and interact with a variety of antiarrhythmic drugs, such as amiodarone and digoxin, which can increase the risk of adverse cardiovascular events. Antiviral drugs such as ritonavir can interact with nonvitamin K-dependent oral antiplatelet agents such as clopidogrel. The combination of ribavirin and IFN-α may aggravate the dysfunction of vascular endothelial cells caused by the virus (Schmidt et al., 2020) . Therefore, the combination of ribavirin and IFN-α is not recommended for the treatment of COVID-19 infection. Chloroquine is primarily metabolized by the kidney and should not be combined with inhibitors of CYP1A1, CYP2D6, and CYP3A4 such as lopinavir/ritonavir. There are drug interactions between arbidol and CYP3A4 inhibitors or inducers, and long-term use of arbidol and CYP3A4 inhibitors or inducers can lead to cardiac toxicity (Liu et al., 2009) . Tocilizumab can alter lipid metabolism and should not be combined with lopinavir/ ritonavir (Gabay et al., 2016) . Generally, it is not recommended to use three or more antiviral drugs at the same time. In case of intolerable adverse effects, the relevant drugs should be stopped (NHC, 2020a). Inappropriate use of antibacterials, especially the combination of three or more broad-spectrum antibacterial drugs should be avoided in patients with COVID-19 infection because that there were many complications such as hypertension, hyperglycemia, fever, dry cough, and dyspnea . Although corticosteroids have the action to reduce the severity of myocarditis and cytokine storm in COVID-19 patients, they inhibit viral RNA clearance. Therefore, it recommends using COVID-19 patients with severe symptoms Russell et al., 2020) . In addition, the intravenous transplantation of mesenchymal stem cells (MSC) can improve the condition of patients with COVID-19, especially for critical cases (Leng et al., 2020) . It specifically demonstrated that increased peripheral lymphocytes and IL-10, decreased C-reactive protein and TNF-α, and disappear of the overactivated cytokine-secreting immune cells, such as CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells, after MSC treatment compared to those in the placebo control group. The principles of treatment in severe and critical cases include symptomatic treatment, prevention of complications and secondary infections, treatment of underlying diseases, and timely maintenance of organ function. The main measures of organ function support are respiratory support (oxygen therapy and mechanical ventilation), circulatory support (liquid balance strategy, improvement of blood circulation with hemodynamic monitoring), and renal replacement therapy in patients with renal dysfunction, plasma therapy from convalescent patients, and blood purification (plasma exchange, adsorption, perfusion, filtration) (NHC, 2020b). HuoxiangZhengqi capsules (HXZQ) -藿香 正气胶囊 Fatigue with gastro-intestinal discomfort , Tong et al. (2020) , Wang et al. (2020f) LianhuaQingwen capsules (LHQW) -连花 清瘟胶囊 Once COVID-19 patients are treated, medical personnel must pay attention to baseline cardiovascular health and adjust the treatment plan in time according to changes in heart rate, blood pressure, blood lipids, cardiac function, and electrocardiogram. Medical staff should also take note of drug-drug interactions to avoid drug-induced myocardial injury. In addition, indexes of myocardial injury and cardiac function should be monitored by combining laboratory and imaging results. Clinicians need to continue to assess the efficacy of combination drugs. Combining of three or more antiviral drugs is not recommended, especially in elderly patients. Although progress has been made in the search for drugs to treat infection, a reliable drug screening model in vitro and in vivo should be built with collaborative innovation. Kaletra Prescribing Information KALETRA-lopinavir and ritonavir tablet, film coated Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019 Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. SN Compr Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques Kawasaki-like disease in children with COVID-19 COVID-19 and the Heart Tocilizumab for the treatment of severe coronavirus disease 2019 The novel coronavirus (COVID-19) and the risk of Kawasaki disease in children The possible of immunotherapy for COVID-19: A systematic review The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19 Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Cardiovascular disease and COVID-19 Cardiovascular disease and COVID-19: les liaisons dangereuses COVID-19 update: Covid-19-associated coagulopathy Remdesivir for the Treatment of Covid-19 -Final Report Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease? Arbidol as a broad-spectrum antiviral: An update Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Convalescent plasma to treat COVID-19 Deployment of convalescent plasma for the prevention and treatment of COVID-19 Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study Frontiers in Pharmacology | www.frontiersin.org Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized IFN-α negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: implications for systemic lupus erythematosus Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact Beneficial impact of Baricitinib in COVID-19 moderate pneumonia A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 The convalescent sera option for containing COVID-19 Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Information for Clinicians on Investigational Therapeutics for Patients with COVID-19 The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)-China Traditional Chinese medicine for combating COVID-19 Convalescent plasma as a potential therapy for COVID-19 Emerging coronaviruses: Genome structure, replication, and pathogenesis Restructuring Structural Heart Disease Practice during the COVID-19 Pandemic: JACC Review Topic of the Week Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study An interactive web-based dashboard to track COVID-19 in real time Natural history of COVID-19 and current knowledge on treatment therapeutic options Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems during the COVID-19 Pandemic Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP) Effectiveness of convalescent plasma therapy in severe COVID-19 patients Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis Safety profile of the antiviral drug remdesivir: An update Baricitinib for COVID-19: a suitable treatment? Chloroquine and hydroxychloroquine in covid-19 Commentary: What is the relationship between Covid-19 and cardiovascular disease? Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with COVID-19 Diagnosis and Mortality Targeting the NLRP3 Inflammasome in Severe COVID-19 Why tocilizumab could be an effective treatment for severe COVID-19? Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis Structure of the RNA-dependent RNA polymerase from COVID-19 virus Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19. medRxiv Frontiers in Pharmacology | www.frontiersin.org Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers Characterization of Myocardial Injury in Patients with COVID-19 The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good Marked Sinus Bradycardia Associated with Remdesivir in COVID-19: A Case and Literature Review Cardiac Adverse Events with Remdesivir in COVID-19 COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options Hyperinflammation with COVID-19: The key to patient deterioration? Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics) Initial COVID-19 affecting cardiac patients in China Traditional Chinese Medicine for Cardiovascular Disease COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Compr Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis Clinical features of patients infected with 2019 novel coronavirus in Wuhan Anakinra for severe forms of COVID-19: a cohort study Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial CSANZ COVID-19 Cardiovascular Nursing Care Consensus Statement: Executive Summary Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review Costeffectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa COVID-19 Global Map in COVID-19 dashboard by the CSSE at JHU COVID-19 Resource Center Dexamethasone in the management of covid -19 Safety Update: COVID-19 Convalescent Plasma Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 Cardiovascular manifestations and treatment considerations in COVID-19 Disruptive Modifications to Cardiac Critical Care Delivery during the Covid-19 Pandemic: An International Perspective A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv Anakinra Treatment in Critically ill COVID-19 Patients: A Prospective Cohort Study Cardiovascular complications in COVID-19: A systematic review and meta-analysis Long-acting β2-adrenoreceptor agonists suppress type 1 interferon expression in human plasmacytoid dendritic cells via epigenetic regulation Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection A current review of COVID-19 for the cardiovascular specialist Early identification of COVID-19 cytokine storm Frontiers in Pharmacology | www Chloroquine hype is derailing the search for coronavirus treatments Potential role of statins in COVID-19 Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia The use of dexamethasone in the treatment of COVID-19 Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) Worrying situation regarding the use of dexamethasone for COVID-19 Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Advances in the molecular mechanisms of NLRP3 inflammasome activators and inacativators Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Traditional Chinese medicine contributes to the treatment of COVID-19 patients Pharmacokinetic properties and bioequivalence of two formulations of arbidol: An open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers The Science Underlying COVID-19: Implications for the Cardiovascular System Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Cardiovascular complications in COVID-19 Common adverse events associated with ribavirin therapy for Severe Fever with Thrombocytopenia Syndrome Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System Analysis on herbal medicines utilized for treatment of COVID-19 Tocilizumab treatment in COVID-19: A single center experience Longterm follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin Potential Effects of Coronaviruses on the Cardiovascular System: A Review COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking Management of Acute Myocardial Infarction during the COVID-19 Pandemic An Urgent Need for Studies of the Late Effects of SARS-CoV-2 on the Cardiovascular System Emerging Treatments in COVID-19: Adverse Drug Reactions Including Drug Hypersensitivities Antiviral activities of type I interferons to SARS-CoV-2 infection Baricitinib: First Global Approval Impact of COVID-19 on the Cardiovascular System: A Review Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Testing Positive for Coronavirus Disease 2019 (COVID-19) Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Cardiac effects and toxicity of chloroquine: a short update First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19 A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. New Engl Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome Endothelial dysfunction in COVID-19: Current findings and therapeutic implications Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series Genetic Analysis of Leukocyte Type-I Interferon Production and Risk of Coronary Artery Disease National Health Commission of the People's Republic of China: Guideline on diagnosis and treatment of COVID-19 National Health Commission of the People's Republic of China: Notice on novel coronavirus pneumonia diagnosis and treatment plan Combating COVID-19 with integrated traditional Chinese and Western medicine in China Therapeutic Management of Adults With COVID-19 COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives Lopinavir/ritonavir: a review of its use in the management of HIV infection Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk Anakinra for patients with COVID-19: a meta-analysis of nonrandomized cohort studies Dexamethasone: A boon for critically ill COVID-19 patients? Convalescent plasma is ineffective for covid-19 Adverse side-effects to biological agents Recent discovery and development of inhibitors targeting coronaviruses Corticosteroids in COVID-19 ARDS: Evidence and Hope during the Pandemic Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis Traditional Chinese medicine for COVID-19 treatment Research progress of traditional Chinese medicine against COVID-19 Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ ritonavir) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Convalescent Plasma to Treat COVID-19: Possibilities and Challenges Convalescent plasma for patients with severe COVID-19: a matched cohort study Drug Evaluation during the Covid-19 Pandemic Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in Cytokine storm syndrome in severe COVID-19 Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Type 1 interferons as a potential treatment against COVID-19 Emerging pharmacotherapies for COVID-19 COVID-19, Hypercoagulability, and Cautiousness with Convalescent Plasma Effects of chloroquine on viral infections: an old drug against today's Frontiers in Pharmacology | www Sofosbuvir as Repurposed Antiviral Drug against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial? Interferon-and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19) COVID-19: A Concern for Cardiovascular Disease Patients Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia Side Effects of Interferon-α Therapy Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial COVID-19: combining antiviral and anti-inflammatory treatments Association between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients with COVID-19: A Meta-analysis ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19 Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? The potential insights of Traditional Chinese Medicine on treatment of COVID-19 Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic Artemisinin-A Gift from Traditional Chinese Medicine to the World (Nobel Lecture) Immunology of COVID-19: current state of the science Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein? Endothelial cell infection and endotheliitis in COVID-19 Dexamethasone and remdesivir: finding method in the COVID-19 madness Global virus outbreaks: Interferons as 1st responders Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 The antiinfluenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro The pros and cons of traditional Chinese medicines in the treatment of COVID-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Coronavirus disease (COVID-2019) situation reports. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients COVID-19 and toxicity from potential treatments: Panacea or poison An Update on Current Therapeutic Drugs Treating COVID-19 Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients Traditional Chinese Medicine treatment of COVID-19 Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study Effective treatment of severe COVID-19 patients with tocilizumab Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 Treatment with convalescent plasma for COVID-19 patients in Wuhan Frontiers in Pharmacology | www.frontiersin.org The pathogenesis and treatment of the`Cytokine Storm' in COVID-19 Current Treatments for COVID-19 Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China Is traditional Chinese medicine useful in the treatment of COVID-19? Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alphaketoamide inhibitors Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19 ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and metaanalysis Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19 Current targeted therapeutics against COVID-19: Based on first-line experience in China COVID-19 and the cardiovascular system Traditional Chinese medicine A pneumonia outbreak associated with a new coronavirus of probable bat origin Arbidol monotherapy is superior to lopinavir Conflict of Interest: The authors declare that the research was conducted in the Aouba et al. (2020) , Bilia et al. (2020) , Bozzi et al. (2021) , Cauchois et al. (2020 ), Cavalli et al. (2020 , Dos Santos, DL and XZ generated the concept for this review, performed the literature search, and contributed equally to this work. ZD, FL, JM, and XW revised the draft. DL and XW guided the study. All authors have read and approved the final manuscript. The study was funded by Natural Science Foundation of He'nan Province of China (202300410313), the Postdoctoral Science Foundation of China (2020M683183), and the Scientific Research Foundation of Xinxiang Medical University (BSKYZZ201628, 300/ 505186 and BSKYZZ201706, 300/505233), the National Natural Science Foundation of China (81873459 and U1804166).